Literature DB >> 29778464

Peroxiredoxin 2 deficiency accelerates age-related ovarian failure through the reactive oxygen species-mediated JNK pathway in mice.

Sun-Ji Park1, Jung-Hak Kim2, Dong Gil Lee3, Jin-Man Kim4, Dong-Seok Lee5.   

Abstract

Reactive oxygen species (ROS) produced in biological reactions have been shown to contribute to ovarian aging. Peroxiredoxin 2 (Prx2) is an antioxidant enzyme that protects cells by scavenging ROS; however, its effect on age-related, oxidative stress-associated ovarian failure has not been reported. Here, we investigated its role in age-related ovarian dysfunction and 4-vinylcyclohexene diepoxide (VCD)-induced premature ovarian failure using Prx2-deficient mice. Compared to those in wildtype (WT) mice, serum levels of anti-Müllerian hormone, 17β-estradiol, and progesterone and numbers of follicles and corpora lutea were significantly lower in 18-month-old Prx2-/- mice. Moreover, levels of Bax, cytochrome c, cleaved caspase-3, and phosphorylated JNK proteins were higher and numbers of apoptotic (terminal deoxynucleotidyl transferase dUTP nick end labeling-positive) cells were considerably greater in 18-month-old Prx2-/- ovaries than WT ovaries. Furthermore, the effects of the ovarian toxicant VCD in significantly enhancing ROS levels and apoptosis through activation of JNK-mediated apoptotic signaling were more pronounced in Prx2-/- than WT mouse embryonic fibroblasts. Expression of the steroidogenic proteins StAR, CYP11A1, and 3β-HSD and serum levels of 17β-estradiol and progesterone were also reduced to a greater extent in Prx2-/- mice than WT mice after VCD injection. This reduced steroidogenesis was rescued by addition of the Prx mimic ebselen or JNK inhibitor SP600125. This constitutes the first report that Prx2 deficiency leads to acceleration of age-related or VCD-induced ovarian failure by activation of the ROS-induced JNK pathway. These findings suggest that Prx2 plays an important role in preventing accelerated ovarian failure by inhibiting ROS-induced JNK activation.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  4-vinylcyclohexene diepoxide; Aging; Ovarian failure; Oxidative stress; Peroxiredoxin 2

Mesh:

Substances:

Year:  2018        PMID: 29778464     DOI: 10.1016/j.freeradbiomed.2018.05.059

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  7 in total

Review 1.  Effects of Peroxiredoxin 2 in Neurological Disorders: A Review of its Molecular Mechanisms.

Authors:  Jifei Liu; Gang Su; Juan Gao; Ye Tian; Xiaoyan Liu; Zhenchang Zhang
Journal:  Neurochem Res       Date:  2020-01-30       Impact factor: 3.996

Review 2.  Peroxiredoxin, Senescence, and Cancer.

Authors:  Mengyao Wu; Chujun Deng; Tak-Ho Lo; Ka-Ying Chan; Xiang Li; Chi-Ming Wong
Journal:  Cells       Date:  2022-05-28       Impact factor: 7.666

3.  Direct Imaging of Lipid Metabolic Changes in Drosophila Ovary During Aging Using DO-SRS Microscopy.

Authors:  Yajuan Li; Pegah Bagheri; Phyllis Chang; Audrey Zeng; Jie Hao; Anthony Fung; Jane Y Wu; Lingyan Shi
Journal:  Front Aging       Date:  2022-02-03

4.  Peroxiredoxin 4, a new oxidative stress marker in follicular fluid, may predict in vitro fertilization and embryo transfer outcomes.

Authors:  Qian Yi; Chao Meng; Ling-Bo Cai; Yu-Gui Cui; Jia-Yin Liu; Yan Meng
Journal:  Ann Transl Med       Date:  2020-09

5.  PRDX2 Protects Against Atherosclerosis by Regulating the Phenotype and Function of the Vascular Smooth Muscle Cell.

Authors:  Jing Li; Cong Wang; Wenjing Wang; Lingzi Liu; Qingqing Zhang; Jun Zhang; Bo Wang; Shujing Wang; Li Hou; Chuanzhou Gao; Xiao Yu; Lei Sun
Journal:  Front Cardiovasc Med       Date:  2021-03-11

6.  Systematic Characterization of Prognostic Values of Peroxiredoxin Family in Gastric Cancer.

Authors:  Rui Xu; Jiadong Pan; Jie Mei; Qinglin Zhang
Journal:  Biomed Res Int       Date:  2020-01-09       Impact factor: 3.411

Review 7.  Knockout Mouse Models for Peroxiredoxins.

Authors:  Young Jae Lee
Journal:  Antioxidants (Basel)       Date:  2020-02-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.